Literature DB >> 8872970

Renal involvement in von Hippel-Lindau disease.

D Chauveau1, C Duvic, Y Chrétien, F Paraf, D Droz, P Melki, O Hélénon, S Richard, J P Grünfeld.   

Abstract

Renal involvement in von Hippel-Lindau (VHL) disease has emerged as the most prevalent cause of death in this hereditary disorder. In a group of 43 VHL patients (23 unrelated families) with renal lesions we examined whether severity of renal disease is affected by parental inheritance and VHL subtype (1, without pheochromocytoma; 2, with pheochromocytoma). We also tested whether and how nephron-sparing surgery could be applied. Renal involvement comprised multiple cysts and bilateral and multifocal carcinomas (RCC) which were detected by screening in 38 patients, at 30.5 (14 to 62) years of age. The severity of the renal disease was similar in VHL type 1 (79% of the pedigrees) and 2 (21%). It was not influenced by the sex of the carrier. Twenty-nine patients were operated on at a mean age of 33.6 years: 21 patients (28 kidneys or 61% of all operated kidneys) underwent nephron-sparing surgery, 4 had complete ablation of involved kidneys and thus required dialysis, 3 had uninephrectomy and 1 had cyst fenestration. Vascular thrombosis was the most severe early complication. It occurred in 4 of 9 kidneys treated by ex vivo surgery. During a median follow-up of 29 months, local recurrence occurred in 5 of 21 (24%) patients treated by nephron-sparing surgery, whereas 2 developed metastasis. Chronic renal failure (creatinine > 120 mumol/liter) affected 11 patients; in 9 of them, it was due to sequelae of surgery. In conclusion, screening of RCC and nephron-sparing surgery are of value in VHL patients. However, indications of ex vivo surgery should be drastically restricted and renal sequelae are not uncommon. Renal followup is required because of the risk of recurrence.

Entities:  

Mesh:

Year:  1996        PMID: 8872970     DOI: 10.1038/ki.1996.395

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  13 in total

1.  Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights.

Authors:  Maria I Carlo; A Ari Hakimi; Grant D Stewart; Gennady Bratslavsky; James Brugarolas; Ying-Bei Chen; W Marston Linehan; Eamonn R Maher; Maria J Merino; Kenneth Offit; Victor E Reuter; Brian Shuch; Jonathan A Coleman
Journal:  Eur Urol       Date:  2019-07-18       Impact factor: 20.096

2.  CT and MRI appearances and radiologic staging of pediatric renal cell carcinoma.

Authors:  Ryan T Downey; Jonathan R Dillman; Maria F Ladino-Torres; Jonathan B McHugh; Peter F Ehrlich; Peter J Strouse
Journal:  Pediatr Radiol       Date:  2012-01-17

Review 3.  Von Hippel-Lindau disease: a single gene, several hereditary tumors.

Authors:  J Crespigio; L C L Berbel; M A Dias; R F Berbel; S S Pereira; D Pignatelli; T L Mazzuco
Journal:  J Endocrinol Invest       Date:  2017-06-06       Impact factor: 4.256

4.  Involvement of hypoxia-inducible transcription factors in polycystic kidney disease.

Authors:  Wanja Michael Bernhardt; Michael Sean Wiesener; Alexander Weidemann; Roland Schmitt; Wilko Weichert; Philipp Lechler; Valentina Campean; Albert Chee Meng Ong; Carsten Willam; Norbert Gretz; Kai-Uwe Eckardt
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

Review 5.  Epidemiology and staging of renal cell carcinoma.

Authors:  Carole A Ridge; Bradley B Pua; David C Madoff
Journal:  Semin Intervent Radiol       Date:  2014-03       Impact factor: 1.513

6.  Clinical characteristics and genetic testing of an atypical familial von Hippel-Lindauzon renal cell carcinoma.

Authors:  Jing Wang; Feng Qi; Ping Zhang; Zicheng Xu; Yuxiao Zheng; Hongzhou Cai; Bin Yu; Ting Xu; Xiao Li; Qing Zou
Journal:  Ann Transl Med       Date:  2019-11

Review 7.  MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma.

Authors:  Elshad Hasanov; Eric Jonasch
Journal:  Expert Opin Investig Drugs       Date:  2021-05-20       Impact factor: 6.206

Review 8.  Modes of action of trichloroethylene for kidney tumorigenesis.

Authors:  L H Lash; J C Parker; C S Scott
Journal:  Environ Health Perspect       Date:  2000-05       Impact factor: 9.031

9.  ZBRK1, a novel tumor suppressor, activates VHL gene transcription through formation of a complex with VHL and p300 in renal cancer.

Authors:  Ke Chen; Gan Yu; Kiranmai Gumireddy; Anping Li; Weimin Yao; Lu Gao; Shuliang Chen; Jun Hao; Ji Wang; Qihong Huang; Hua Xu; Zhangqun Ye
Journal:  Oncotarget       Date:  2015-03-30

10.  Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer.

Authors:  Sakari Vanharanta; Weiping Shu; Fabienne Brenet; A Ari Hakimi; Adriana Heguy; Agnes Viale; Victor E Reuter; James J-D Hsieh; Joseph M Scandura; Joan Massagué
Journal:  Nat Med       Date:  2012-12-09       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.